About Luma Group
Luma Group is a private equity firm founded in 2023. It is primarily based in New York, United States. In the last 12 months, it has participated in 3 funding rounds.
Overall Luma Group portfolio has seen 1 acquisition, namely ROME Therapeutics. A lot of funds co-invest with Luma Group, with names like Regeneron Ventures sharing a substantial percentage of its portfolio.
Luma Group has a team of 12 people, including 4 partners.
Key Metrics
Luma Group's Portfolio
They have invested in a total of 7 companies. Their most recent investment was in Coultreon (Series A round) on Apr 28, 2026. Here is the most recent investment by Luma Group:Date | Company | Round | Amount | Co-Investors |
|---|---|---|---|---|
Apr 28, 2026 | Series A | 5145 | ||
Nov 18, 2025 | Series B | 2474 | ||
Oct 29, 2025 | Series A | 8491 | ||
Mar 26, 2025 | Series B | 2796 |
_1570600365539.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Here is the portfolio snapshot of Luma Group:
Investments by Year
The maximum number of investments were made in 2025
Team profile of Luma Group
Luma Group has a team of 12 members including 4 Partners, 1 Venture Partner and 1 Principal located in United States and United Arab Emirates. Luma Group's team does not sit on the board of any company as of now.Here is a list of top team members in Luma Group:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | San Francisco | - | ||
Partner | - | - | - | |
Partner | - | - | ||
Partner | Chicago | - | ||
Venture Partner | San Francisco | - | ||
Principal | New York City | - | ||
Advisor | United Arab Emirates | - | ||
Advisor | New York City | - | ||
Advisor | New York | - | - | |
Associate | New York | - | ||
Associate | New York | - | - |
Co-investors of Luma Group
Over the past 3 years, 32 investors have co-invested in Luma Group's portfolio companies.
- Top Co-investors of Luma Group: 32 investors entered a company along with Luma Group. These include investors like Regeneron Ventures (2 companies).
Luma Group News
•
Coultreon Biopharma Secures $125M Series A to Advance Immunology PipelineBioSpace•Apr 28, 2026•Novo Holdings, Forbion, Sofinnova Investments, Finchley Healthcare Ventures and 16 others
•
Aeovian gets $55M for tuberous sclerosis complex, to explore prospects in obesityEndpoints•Dec 16, 2025•Aeovian Pharmaceuticals, Hevolution, Sofinnova Investments, CTI Life Sciences Fund and 7 others
•
Character Biosciences gains $93m for precision eye disease therapiesPharmaceutical Technology•Mar 27, 2025•Character Biosciences, Luma Group, aMoon, Bausch & Lomb
•
Character Biosciences Secures $93 Million in Series B Funding to Advance Precision Medicine for Progressive Eye DiseasesVision Monday•Mar 27, 2025•Character Biosciences, aMoon, Luma Group, Bausch & Lomb and 8 others
•
ArsenalBio secures $325m to develop cell therapy programmesPharmaceutical Technology•Sep 05, 2024•ArsenalBio, Arch Venture Partners, Luma Group, Milky Way Holdings and 14 others
